Pomalidomide shows promise in boosting immune response in myeloma

Pomalidomide(Pomalidomide) is a new type of immunomodulatory drug that has attracted widespread attention in the treatment of multiple myeloma (MM) in recent years. Multiple myeloma is a blood cancer that primarily affects plasma cells in the bone marrow. The disease not only causes bone marrow dysfunction but also significantly weakens patients' immune systems, making them more susceptible to infections and other complications. Although treatments have improved in recent years, due to the extremely high recurrence rate of multiple myeloma, new treatment strategies are urgently needed to improve patients' survival rate and quality of life.

Research shows that adding pomalidomide to standard treatment regimens is expected to enhance patients' immune responses and thereby improve their outcomes. Patients who received pomalidomide along with standard drugs such as boraxozomib, dexamethasone or lenalidomide showed stronger immune responses than those who did not receive pomalidomide. The discovery provides new insights into re-evaluating treatments for multiple myeloma.

Clinical trial data showed that patients treated with pomalidomide had a significantly longer time without disease progression, reaching 20.7 months, compared with only 11.6 months for patients who did not receive the drug. This important data shows that pomalidomide helps the body better recognize and destroy cancer cells by enhancing the activity of key immune cells, such as T cells and natural killer cells [NK cells].

At the molecular level, pomalidomide's mechanism of action involves its effects on proteins that suppress immune function. Specifically, the drug promotes targeting of the CRL4 E3 ubiquitin ligase, leading to the degradation of the T cell repressors Ikaros and Aiolos. This process helps restore the normal function of immune cells, allowing the immune system to fight tumor cells more effectively. In addition, pomalidomide can also affect a variety of cell signaling pathways to further enhance immune responses.

The immune-enhancing effects of pomalidomide make it a valuable option for patients whose myeloma has relapsed after prior treatment with other treatments. Numerous studies have demonstrated that pomalidomide can slow disease progression and improve patient survival by restoring immune cell function. This is undoubtedly a new hope for patients who face limited treatment options.

As pomalidomide is studied more intensively, more and more evidence supports its key role in the treatment of multiple myeloma. The drug not only improves progression-free survival (PFS) but may also provide better outcomes for patients by enhancing overall immune function. In addition, the effect of pomalidomide is more significant when used in combination with other therapies, demonstrating its good potential for combination therapy.

In conclusion, pomalidomide, as an effective immunomodulatory drug, brings new hope for the treatment of multiple myeloma. Its ability to strengthen the immune system and improve progression-free survival provides a new treatment strategy for many patients with refractory multiple myeloma.

Reference materials:https://www.news-medical.net/news/20250123/Pomalidomide-shows-promise-in-enhancing-immune-responses-in-myeloma.aspx